IMM vs. FARN, ARIX, CIR, BVXP, 4BB, TILS, VSN, SCLP, MPH, and ORPH
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry.
ImmuPharma vs. Its Competitors
ImmuPharma (LON:IMM) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.
ImmuPharma is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.
ImmuPharma has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Faron Pharmaceuticals Oy has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.
6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 2.9% of Faron Pharmaceuticals Oy shares are held by institutional investors. 8.1% of ImmuPharma shares are held by insiders. Comparatively, 4.1% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ImmuPharma has a net margin of 3,519.56% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 0.46% beat ImmuPharma's return on equity.
In the previous week, ImmuPharma had 1 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 2 mentions for ImmuPharma and 1 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 1.20 beat ImmuPharma's score of 0.37 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.
Summary
ImmuPharma beats Faron Pharmaceuticals Oy on 8 of the 11 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 10/9/2025 by MarketBeat.com Staff
